Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Avricore Health Inc. files with the SEC in its annual reports.
In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
0.03
0.12
1.77
3.48
4.66
Cost of revenue
0
0.71
0
0.02
0.02
0.02
0.09
1.31
2.28
2.91
Gross profit
0
0.3
0
-0
0.01
0.02
0.03
0.46
1.2
1.88
Research and development
0.06
0.21
0.24
0.25
Selling and marketing
0.01
0.66
0.07
0.28
0.25
0.03
Interest expense
0
0
0
0
0.01
0.16
0.04
Pre-tax income
-1.75
-0.82
-0.69
0.13
Income from continuing operations
-1.3
-3.46
-1.92
-1.17
0.04
-0
Net income
-2.2
-2.61
-1.3
-3.46
-1.92
-1.17
-1.71
-0.82
-0.7
-0.67
EPS, basic
-0.04
-0.02
-0.02
-0.01
-0.01
-0.01
EPS, diluted
-0.04
-0.02
-0.02
-0.01
-0.01
-0.01
Balance sheet
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
2.72
0.43
0.56
0.08
0.01
0.3
2.01
0.62
0.28
1.13
Receivables
0.72
0.45
0.28
0.02
0.01
0.09
0.77
0.43
0.42
Inventory
1.06
0.21
0.1
0
0.02
0
Total current assets
2.24
1.67
0.75
0.21
0.44
2.16
1.43
0.77
1.58
Property, plant and equipment
0.03
0.09
0.02
0
0
0.09
1.11
1.72
0.66
Lease right-of-use assets
0
Total assets
2.28
2.9
1.2
0.21
0.44
2.28
2.57
2.54
2.3
Accounts payable
0.36
0.3
0.31
0.65
0.15
0.04
0.31
0.2
Lease liabilities
0
Total liabilities
0.36
0.4
0.31
0.67
1.15
0.08
0.6
0.53
0.33
Total debt
0.04
Retained earnings
-14.6
-18.4
-21.1
-25.2
-27.3
-28.5
-30.2
-31
-31.7
-32.4
Total equity
3.35
1.92
2.5
0.89
-0.47
-0.72
2.2
1.96
2.01
1.97
Total liabilities and equity
2.28
2.9
1.2
0.21
0.44
2.28
2.57
2.54
2.3
Cash flow statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-2.2
-2.61
-1.3
-3.46
-1.92
-1.17
-1.71
-0.82
-0.7
-0.67
Depreciation and amortization
0.01
0
0.53
0.18
0
0.02
0
0
0
Cash from operations
-1.48
-2.06
-1.04
-1.41
-0.69
-1.22
-1.23
-0.44
0.66
1
Capital expenditures
-0.03
-0.01
-0
-0.01
-0.11
-1.19
-1.02
-0.18
Cash from investing
-0.03
-0.01
-0.13
-0.15
0
0
-0.14
-1.21
-1.05
-0.21
Debt repaid
-0.03
0
0
-1
Stock issued
0.85
0
0.45
0.6
0
0
2.4
Cash from financing
3.94
0.36
2.03
1.4
0.62
1.51
3.08
0.25
0.04
0.06
Exchange rate effect
-0
Net change in cash
2.43
-1.71
0.13
-0.48
-0.07
0.29
1.71
-1.39
-0.34
0.86
Free cash flow
-1.52
-2.07
-1.04
-1.42
-1.34
-1.63
-0.36
0.82
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
40.4%
Gross profit / revenue.
Pre-tax margin
2.8%
Pre-tax income / revenue.
Net margin
-14.4%
Net income / revenue.
FCF margin
17.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
21.6%
Cash from operations / revenue.
Return on assets (ROA)
-27.7%
Net income / average total assets.
Capex / revenue
3.9%
Capital expenditures / revenue.
D&A / revenue
0.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
33.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
236.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
56.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
295.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
164.6%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
52.1%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-9.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
0.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
61.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Liabilities / assets
14.4%
Total liabilities / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
1.93x
Revenue / average total assets.
Fixed asset turnover
3.92x
Revenue / average property, plant and equipment.
Inventory turnover
274x
Cost of revenue / average inventory.
Days inventory
1 days
365 x average inventory / cost of revenue.
Receivables turnover
11.0x
Revenue / average receivables.
Days sales outstanding
33 days
365 x average receivables / revenue.
Capex / operating cash flow
18.0%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CA$0.01
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CA$0.01
Net income per basic share, as reported (split-adjusted).
What was Avricore Health Inc.'s revenue in fiscal 2024?
Avricore Health Inc. reported revenue of CA$4.7M for fiscal 2024, 33.7% higher than the year before.
Was Avricore Health Inc. profitable in fiscal 2024?
No. It reported a net loss of CA$669.0K.
How much free cash flow did Avricore Health Inc. generate in fiscal 2024?
Cash from operations of CA$1.0M minus capital expenditures of CA$181.1K left free cash flow of CA$823.5K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.